ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, to validate the company’s ProteaseTag® point-of-care technology for real-time management of small airway inflammation in a spectrum of respiratory diseases including Cystic Fibrosis and COPD. ProAxsis’ technology will allow clinicians to measure active Neutrophil Elastase as a potential predictor of chronic respiratory disease exacerbations and severity in COPD and cystic fibrosis, and offers a potential companion diagnostic for disease modifying agents. COPD affects more than 24 million Americans, and is the third leading cause of death. National Jewish Health is the #1 ranked Hospital in Respiratory Disease by US News and World Report 2017.

Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “National Jewish Health is a globally recognised leader in respiratory care and research, so this agreement brings tremendous resources and expertise to our effort to bring the ProteaseTag® technology to market in the US.”

Any queries concerning ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to info@proaxsis.com.